EuroMedtech™ Announces Program Highlights
Carlsbad, USA, Zurich, Switzerland, and Duesseldorf,
Germany, May 12, 2009: EBD Group today announced
that the first annual EuroMedtech™ 2009 partnering event,
June 3–4 at the Maritim Hotel in Duesseldorf, will host
some of the biggest names in the medtech industry. Featured
on panels and workshops, leading decision makers will
tackle key issues vital to the industry’s future.
To learn more about any of the sessions below, please
visit the EuroMedTech 2009 program page at www.ebdgroup.com/emt/program.htm.
Will innovation still thrive in the current market?
— Moderated by Dr. Olivier Litzka, Partner, Life
Sciences, Edmond de Rothschild Investment Partners along
with speakers Dr. William Denman, VP and CMO, Medical
Affairs, Covidien; Dr. Stuart Hendry, CEO, Sphere Medical;
Dr. Jacques Souquet, CEO, Supersonic Imagine and Prof.
Joerg Vienken, VP, BioSciences, Fresenius Medical Care
this session will discuss current markets and economies
and their effect on innovation within the industry.
The promise of molecular biomarkers and diagnostics:
Expectations, hurdles and reality — Marcel van
Kasteel, CEO and GM, Handheld Immunoassays, Philips Healthcare
Incubator will be joined by Alan Carter, VP, Global Business
Development, Agendia; and Dr. Anna Maria Papini, CSO,
Toscana Biomarkers to discuss the expanding platform of
technologies, challenges and how these technologies can
be commercialized.
The new healthcare: How are changing demographics
spurring changes in imaging and monitoring? —
Panelists Dr. Alan Brett, CTO, Optasia Medical; Dr. Ali
Akgun, CEO, Specialty Scanners; and Dr. Hoc-Khiem Trieu,
Head, Integrated Sensors and Actuators, Fraunhofer Institute
of Microelectronic Circuits and Systems will discuss the
shifting demographic demands on technology in healthcare
imaging and monitoring, and what its future holds for
companies and investors.
Investing in European medtech: What's hot and
what's not? — Moderator Dr. Marion Jung, Principal,
Earlybird Venture Capital will lead a panel of experts
featuring Shiva Dustdar, Head, Structured Finance, Life
Sciences and ICT, European Investment Bank; Timothy Haines,
Partner, Abingworth Management; Antoine Papiernik, Managing
Partner, Sofinnova Partners; Dr. Markus Schillo, Principal,
European Investment Fund; and Dr. Alexander von Frankenberg,
Managing Director, High-Tech Gruenderfonds in an analysis
of where the investment money is heading in medtech and
what stimulus and alternative funding is available.
What do you need to know before successfully
entering the US marketplace? — The lure of the
large US market beckons European medtech firms. Dr. Robert
Keefer, Partner, TCG; Dennis Burns, Marketing Director,
Riemser; Glenn Neuman, Director, Scientific Affairs, New
World Regulatory Solutions; and Dr. Detlef Wilke, former
Chairman Cursan, Managing Director, Dr. Wilke & Partner,
will provide a roadmap for successfully entering the US
marketplace.
A challenge of adoption: Experiences of mature
and next generation cardio and neuro companies
— Moderator Jeanne Bertonis, CEO, Strategic
Biomedical Consultants and panelists Dr. Erik Baas, Director,
Medicine and Technology, International, Medtronic; André-Michel
Ballester, CEO, Sorin Group; Paul Krell, CEO, CNSystems
Medizintechnik; and Dr. Helmut Straubinger, CEO, JenaValve
will discuss what it takes to launch a successful product
in this vital sector and what M&A activities are taking
place.
Ground breaking opportunities in regenerative
medicine and orthopedics — With the introduction
of biological and new materials to wound healing and orthopedics,
speakers Anthony Viscogliosi, Chairman and CEO, Small
Bone Innovations; Dr. William Dolphin, CEO, Avita Medical;
Daniel Green, CEO, BioCeramic Therapeutics; and Robert
Guilleaume, CEO, Resoimplant will review key considerations,
strategies, and pivotal tactics for commercialization
of new advances in orthopedics and regenerative medicine.
About EBD Group
EBD Group is the leading partnering firm for the global
life science industry. Since 1993, biotech, pharma and
medical device companies have leveraged EBD Group’s partnering
conferences, technology and services to identify business
opportunities and develop strategic relationships essential
to their success. EBD Group’s conferences are run with
the support of leading corporations and international
trade associations and include:
- BIO-Europe and BIO-Europe Spring®, the
world's largest stand-alone life science partnering
conferences, supported by the Biotechnology Industry
Organization (BIO)
- BioPharm America™, EBD Group’s North American partnering
event
- EuroMedtech™, EBD Group’s new partnering event for
the innovative medical technology industry
- BioEquity Europe, the investor conference co-organized
with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated
biotech/pharma partnering conference in China
EBD Group’s sophisticated web-based partnering service,
partneringONE™, is used as the partnering engine at numerous
third-party events around the world. Outside of the conference
format, EBD Group’s consultants provide hands-on assistance
for firms seeking to in- or out-license products and technologies.
EBD Group has offices in the USA and Europe.
